Literature DB >> 6988200

Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections.

R C Heel, R N Brogden, G E Pakes, T M Speight, G S Avery.   

Abstract

Miconazole is an imidazole antifungal drug which has recently become available for systemic use. Its antifungal activity has been well studied and it is active in vitro against a wide range of fungi. Published and unpublished reports of the use of miconazole in conditions such as systemic or mucocutaneous candidosis, coccidioidomycosis, fungal meningitis, and paracoccidioidomycosis (which seems especially responsive) have often been encouraging, particularly in view of the serious, refractory nature of the conditions treated, but in most areas of use experience is limited. There are few effective drugs available for treating most systemic fungal infections, and if further studies confirm the encouraging results often seen to date, miconazole will be an important addition to the limited choices available for such conditions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988200     DOI: 10.2165/00003495-198019010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  80 in total

1.  Round table discussion: miconazole(1)tolerance and toxicity (2) route of administration (3) indications for use.

Authors:  R Vanbreuseghem
Journal:  Proc R Soc Med       Date:  1977

2.  Side effects of miconazole for systemic mycoses.

Authors: 
Journal:  N Engl J Med       Date:  1977-10-06       Impact factor: 91.245

3.  Miconazole in the treatment of systemic fungal infections.

Authors:  D Stevens
Journal:  Am Rev Respir Dis       Date:  1977-11

4.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans.

Authors:  H van den Bossche; G Willemsens; W Cools; W F Lauwers; L Le Jeune
Journal:  Chem Biol Interact       Date:  1978-04       Impact factor: 5.192

5.  Successful treatment of systemic cryptococcosis with miconazole.

Authors:  M E Morgans; M E Thomas; D W Mackenzie
Journal:  Br Med J       Date:  1979-07-14

6.  Unusual serum lipoprotein abnormality induced by the vehicle of miconazole.

Authors:  A G Bagnarello; L A Lewis; M C McHenry; A J Weinstein; H K Naito; A J McCullough; R J Lederman; T L Gavan
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

7.  Use of miconazole for prevention of opportunistic fungal infection during treatment of haematological malignancies.

Authors:  J L Michaux; P Jacquemin; G Cornu; G Wauters; J Gigi; H Noel; J B Turine; A Ferrant
Journal:  Proc R Soc Med       Date:  1977

8.  Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis.

Authors:  G Schär; F H Kayser; M C Dupont
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

9.  Miconazole for treatment of disseminated coccidioidomycosis. Unfavorable experience.

Authors:  R D Meyer; F R Sattler; S R Linné; J Ruskin
Journal:  Chest       Date:  1978-06       Impact factor: 9.410

10.  Miconazole treatment of relapsed pulmonary blastomycosis.

Authors:  H D Rose; B Varkey
Journal:  Am Rev Respir Dis       Date:  1978-08
View more
  23 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 6.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

7.  Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use.

Authors:  E Lefler; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.

Authors:  C Brugnara; L de Franceschi; S L Alper
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

10.  Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.

Authors:  R Guinet; D Nerson; F de Closets; J Dupouy-Camet; L Kures; M Marjollet; J L Poirot; A Ros; J Texier-Maugein; P J Volle
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.